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Abstract
We have reported that pyrroloquinoline quinone (PQQ) improves reproduction, neonatal development, and mitochondrial
function in animals by mechanisms that involve mitochondrial related cell signaling pathways. To extend these
observations, the influence of PQQ on energy and lipid relationships and apparent protection against ischemia reperfusion
injury are described herein. Sprague-Dawley rats were fed a nutritionally complete diet with PQQ added at either 0 (PQQ2)
or 2 mg PQQ/Kg diet (PQQ+). Measurements included: 1) serum glucose and insulin, 2) total energy expenditure per
metabolic body size (Wt
3/4), 3) respiratory quotients (in the fed and fasted states), 4) changes in plasma lipids, 5) the relative
mitochondrial amount in liver and heart, and 6) indices related to cardiac ischemia. For the latter, rats (PQQ2 or PQQ+) were
subjected to left anterior descending occlusions followed by 2 h of reperfusion to determine PQQ’s influence on infarct size
and myocardial tissue levels of malondialdehyde, an indicator of lipid peroxidation. Although no striking differences in
serum glucose, insulin, and free fatty acid levels were observed, energy expenditure was lower in PQQ2 vs. PQQ+ rats and
energy expenditure (fed state) was correlated with the hepatic mitochondrial content. Elevations in plasma di- and
triacylglyceride and b-hydroxybutryic acid concentrations were also observed in PQQ2 rats vs. PQQ+ rats. Moreover, PQQ
administration (i.p. at 4.5 mg/kg BW for 3 days) resulted in a greater than 2-fold decrease in plasma triglycerides during a 6-
hour fast than saline administration in a rat model of type 2 diabetes. Cardiac injury resulting from ischemia/reperfusion was
more pronounced in PQQ2 rats than in PQQ+ rats. Collectively, these data demonstrate that PQQ deficiency impacts a
number of parameters related to normal mitochondrial function.
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Introduction
Although pyrroloquinoline quinone (PQQ) functions as a
bacterial enzymatic cofactor, a role in eukaryotic metabolism
remains to be fully elucidated. PQQ is present in plant and animal
cells and many foods and biological fluids, such as milk, at pM to
nM levels [1–3]. PQQ has been shown to function as an
antioxidant [4–9], cardio- and neuroprotectant [6,9–13], and
has been demonstrated to act as a cell and plant growth factor for
a variety of organisms [14,15].
In animal models, dietary PQQ deprivation results in abnormal
development, immune dysfunction and decreased reproductive
performance [16–18]. Our previous observations using gene array
analysis to assess PQQ nutritional status suggested that PQQ
affects a wide range of genes, most notably genes involved in
mitochondrial-related functions [19]. For example, changes in
gene transcriptional networks indicate that 2–4 percent of the total
genes respond to changes in PQQ status depending on dietary
conditions or pharmacologic administration. The genes that
respond are largely revert to normal levels upon PQQ repletion,
and are associated with cellular stress, mitochondriogenesis, and
cell signaling. Moreover, we have observed [20] that exposure of
mouse Hepa1–6 cells to PQQ results in the activation of cAMP
response element-binding protein (CREB) and peroxisome pro-
liferator-activated receptor-gamma-coactivator-1a (PGC-1a).
PQQ exposure also increases the levels of nuclear respiratory
factor activation (NRF-1 and NRF-2) and Tfam [20]. Such
mechanistic features are in keeping with our prior reports that
dietary PQQ deficiency results in a decrease in mitochondria
amount or number [21]. PQQ-deficient mice and rats have
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liver, lower respiratory control ratios, and lower respiratory
quotients (RQ) than PQQ-supplemented mice [21]. As a
consequence of decreased mitochondria, rats also have defects in
amino acid metabolism, particularly lysine and other amino acids
metabolized primarily in the mitochondria [16].
Given these observations, we hypothesized that rats fed PQQ
deficient diets should also display altered lipid clearance and
energy metabolism. Accordingly, non-diabetic Sprague-Dawley or
diabetic UCD-T2DM rats [22] were fed either a PQQ adequate
or PQQ deficient diet and changes in plasma lipid profiles,
responses to a glucose challenge were measured, and 24 hour
energy expenditures and respiratory quotient (RQ) were mea-
sured. As a functional test, the response to cardiac ischemic injury
was tested owing to the importance of optimal mitochondrial and
fatty acid clearance to minimizing ischemic damage.
Results
Animals, Plasma and Tissue PQQ levels, and Mitochondria
The levels of PQQ in plasma, liver, and heart and the relative
mitochondrial content in liver and heart (based on changes in the
mtDNA/nuclearDNA ratio) are presented in Table 1. Values for
plasma PQQ were markedly reduced when rats were fed PQQ-
diets. Short-term repletion with PQQ (3d) rapidly increased
plasma PQQ levels in rats deprived of PQQ. Rats designated as
adults were beyond sexual maturation (.8 weeks in age) and
weighed 225–250 grams. As reported previously, PQQ depriva-
tion did not cause dynamic changes in body weight as rats or mice
approach sexual maturation [17–19]. The rate of weight gain of
rats fed the amino acid based diet was about 90 percent that
reported previously for rats fed commercial laboratory chow diets
[19].
For the studies related to energy expenditure, 4-week-old rats
were used. The rats were selected from litters of dams fed either
the PQQ2 or PQQ+ diet throughout gestation to obtain two
groups that could be matched with respect to body weighs
(4962 g). For the ischemia reperfusion study, rats (males) were 12
weeks old and weighed 37569 grams.
Prolonged exposure to PQQ2 diets consistently resulted in
reduced mitochondrial contents in liver based on the decrease in
the mtDNA/nuclearDNA ratios compared to rats fed PQQ+ diets
(p, 0.01). For heart tissue, values for the mtDNA/nuclearDNA
ratios also tended to be lower.
Lipid Profiles
Distinct differences in serum lipid profiles were observed.
Plasma di- and triglyceride (DAG and TAG) levels were elevated
(,20–50 %) in both young (weanling) and adult rats fed the
PQQ2 diets compared to rats fed PQQ+ diets (Table 2, Tables
S1, S2, S3, S4, S5, S6, S7, and S8, and Figure 1). These
results are in keeping with data reported previously for mice [21].
In Table 2, values labeled n3, n6, n7, n9, and DM (dimethoxy
moieties derived from plasmalogens) represent families of fatty
acids arising from or influenced by various desaturation pathways.
Examination of individual lipids and lipid classes indicated that
changes in PQQ status did not influence major desaturase or
elongation systems. For example, the n6/n3 ratios, although
elevated, did not differ between groups (e.g., 4163 for neutral lipid
fractions and 2162 for phospholipid fractions (Table 2). The
high values are in keeping with the use of corn oil as the dietary
lipid source (n6/n3 ratio range: 42–46). Given that for specific
fatty acids (e.g., Mead acid, 20:3n9 and arachidonic acid, 20:4n6),
their plasma ratios (20:3n9/20:4n6) can be useful to assess fatty
acid deficiency or defects in fatty acid desaturation pathways,
attention was paid to changes in the ratio [23,24]. For each major
Table 1. Plasma PQQ and mtDNA/nuclear DNA Ratio Levels.
PQQ (nM) in Plasma and Tissues
Parameters PQQ Treatments
1,2
Experiment Designation Tissue PQQ+ PQQ2 PQQ2/+
Lipid Assessment Plasma (Adult) 5.261.3 3.562.1* 17.064.5**
Liver (Adult) 21.3616.4 5.462.6** 26.1617.2
Heart (Adult) 3.461.9 2.461.0* 13.6610.2*
Energy, Glucose, insulin,
FFA Assessment
Plasma
(Weanling/young)
10.164.7 0.7160.35*** 16.462.9
Glucose, insulin, FFA Plasma (Adult) 11.366.7 2.661.35** 18.564.9
Ischemia Reperfusion Plasma (Adult) 10.762.1 0.761.5** ND
mtDNA/NuclearDNA Ratio
3
Lipid Assessment Liver (Adult) 1.060.18 0.7860.12** 1.360.06
Energy, Glucose, insulin,
FFA Assessment
Liver
(Weanling/young)
1.060.18 0.8460.07 1.0660.08
Glucose, insulin, FFA Liver (Adult) 1.0660.19 0.7760.15* 1.2860.19
Heart (Adult) 1.060.21 0.8560.17 1.160.2
Ischemia Reperfusion Liver (Adult) 1.060.08 0.7260.1** 1.160.1
1Rats were fed an amino acid-based semi-purified diet either deficient in PQQ (PQQ2) or with PQQ added at 2 mg/kg diet (PQQ+). Rats initially fed PQQ2 diets were
also repleted with PQQ by i.p. injection (4.5 mg PQQ/Kg BW/24 hours X 3).
2The superscripts *, **, *** represent significance relative to the PQQ+ group at p,0.2; ,0.05; or p,0.01, respectively.
3The relative amounts of liver mitochondrial DNA (mtDNA) and nuclear DNA were measured by real-time PCR. The targeted genes were the nuclear cystic fibrosis and
the mitochondrial nicotinamide adenine dinucleotide dehydrogenase-5 gene. When corresponding values for liver in each experiment are averaged, the liver values
were significant at p,0.01 (PQQ+ vs PQQ2 and PQQ+ vs PQQ 2/+ based on ANOVA analysis using a Bonferoni correction); for heart, p,0.3.
doi:10.1371/journal.pone.0021779.t001
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esters, Table S1; plasma free fatty acids, Table S2; diacylglycer-
ide, Table S3; triacylglyceride, Table S4) the major phospho-
lipid classes and their constituent fatty acids (Lysophosphatidyl-
choline, Table S5; phosphatidylcholine, Table S6;
phosphatidylethanolamine, Table S7; sphingomyelin, Table
S8), most of the values were well below 0.02, whereas values for
the 20:3n9/20:4n6 ratio of .0.2 suggest essential fatty acid
deficiency [24]. Further, no clear differences were observed for
given fatty acids in each fatty acid subclass, except for elevations
corresponding to the increases in the DAG, TAG, and NEFA
fractions associated with rats fed the PQQ2 diet and reversal with
repletion. Trace amounts of trans n7 fatty acids were observed,
most likely arising from the corn oil used as the lipid source.
Fewer changes (PQQ2 vs. PQQ+) were observed for
phospholipids, except for apparent increases in lysophosphatidyl-
choline, phosphatidylcholine, and phosphatidylethanolamine plas-
ma fractions upon acute repletion of rats fed the PQQ2 diet with
PQQ (i.p.). In contrast, a consistent, although highly variable,
reduction in sphingomyelin was observed in the majority of
samples for both adult and weanling rats (Table 2, Table S8,
and Figure 1).
Genes Important to Lipid Metabolism
Previously, we have described changes in hepatic transcription
networks from which the elevations in plasma neutral lipids
(Table 2 and Figure 1) could be predicted [19]. It could be
inferred that the changes in hepatic transcription networks and
elevation in plasma neutral lipids was a consequence of decreases
in mitochondrial amount and the expression of enzymes and
transport proteins associated with b-oxidation [19,20]. As an
extension to these observations additional corroboration, changes
in the levels of PPARa, peroxisomal membrane protein 4, methyl
CoA racemase, and acyl CoA oxidase mRNAs levels were
measured as markers as indirect measures of peroxisomal activity.
Because of its relationship to b-oxidation, fatty acid binding
protein mRNA levels were also determined.
The qRT PCR data (Figure 2) indicated that PQQ
deprivation caused perturbations in the levels of mRNA for most
of the markers in liver and cardiac tissue with statistically
Table 2. Pyrroloquinoline Quinone and Plasma Lipid Composition.
1
Lipid Class
1 Treatment Total Lipid
2 Fatty Acid Composition
1
SFA MUFA PUFA N3 N6 N7 N9 DM
Neutral Lipids (nmol fatty acid per g sample)
2
Cholesterol Ester PQQ+ 12196268 188621 114622 9146233 1563.4 8996231 1663.9 98618 0
PQQ2 12716234 189627 103619 9776195 1363.6 9636192 1463.6 89616 0
PQQ2/+ 1439678 199623 89
{±7.1 1149656 1763.0 1131659 1461.9 74
{±9.0 0
FFA
1 PQQ+ 467683 196644 96616 175625 863.7 166622 1263.4 82612 0
PQQ2 508655 197**±41 10668.0 203**±22 964.8 193** ±23 1164.0 93** ±11 0
PQQ2/+ 3716122 148640 80630 143652 762.4 136650 1164.6 66625 0
Diacylglycerol PQQ+ 5969.8 2764.4 1563.6 1765.8 0.760.6 1665.7 1.860.7 12.663.0 0.560.8
PQQ2 95*±26 34**±7.0 23*±7.0 35*±12 3.8*±2.4 31*±11 2.9*±0.8 20* ±6.3 1.961.6
PQQ2/+ 60613 21**±1.7 1662.3 2369.4 0.860.5 2269.0 1.860.1 1462.4 0.360.1
Triacylglycerol PQQ+ 12676340 319672 298697 6426169 1668 6236163 25672 7 5 690 663
PQQ2 2542*±1239 549**±240 624*±299 1358*±699 36**±21 1315*±672 45**±22 586* ±286 7.463
PQQ2/+ 2177
{±704 533
{{±189 527
{±172 1112
{±340 37
{{±23 1070
{±322 47
{{±25 483
{{±150 462
Phospholipids (nmol fatty acid class per g sample)
2
LysoPC
1 PQQ+ 543658 295632 3765.8 208629 4.861.3 204629 8.361.1 2864.9 1.560.9
PQQ2 621*±68 323643 4064.4 255**±21 6.4**±0.9 249**±20 9.561.5 3063.1 1.962.0
PQQ2/+ 703
{{±6.8 360
{{±22 45
{±4.5 295
{{±19 8.7
{{±1.9 287
{{±17 11
{{61.5 3565.4 1.460.5
PC
1 PQQ+ 20366329 9066148 107615 10176167 4669.0 9706158 3166.0 7768.8 4.761.1
PQQ2 22546624 10116221 122647 11016385 55620 10426373 35616 91627 7.063.7
PQQ2/+ 2462
{{±106 1103
{{±50 12164.5 1229
{{±52 68
{±4.0 1161
{±53 36.764.2 8668.8 6.361.5
PEA
1 PQQ+ 378657 166625 47617 152634 5.661.4 146633 4.261.4 42616 11.263.0
PQQ2 395687 165640 57610 162641 7.361.5 154640 4.861.0 51691 0 . 4 61.6
PQQ2/+ 464
{±15 201
{±15 47621 203
{{±19 9.4
{{±2.4 194
{±17 4.661.8 41619 12.860.8
Sphingomyelin PQQ+ 195684 124660 45617 24611 8651 7 672 614 2 616 0
PQQ2 165684 101656 42620 21610 7631 5 661 . 6 614 0 619 0
PQQ2/+ 2636135 1936107 42616 27613 7641 8 671 61.6 43616 0
1Values are mean 6 SD; Abbreviations: FFA (free fatty acid or non-esterified fatty acids), LysoPC (lysophospholipid), PC (phosphocholine), PEA (N-
acylphosphatidylethanolamine).
2For comparisons: for PQQ+ vs. PQQ2, a single asterisk indicates p,0.05 and two asterisks indicate P,0.1 relative to the PQQ+ group; for PQQ+ vs. PQQ +/2,a
{indicates p,0.05 and {{indicate P,0.1 relative to the PQQ+ group.
doi:10.1371/journal.pone.0021779.t002
Pyrroloquinoline Quinone and Lipid Metabolism
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21779significant changes in fatty acid binding protein, acyl CoA oxidase
and methyl CoA racemase in cardiac tissue, but only for fatty acid
binding protein and in liver. Perhaps owing to the apparent
stability of the peroxisomal markers that were chosen and the
stability of fatty acid binding protein, repletion with PQQ (2/+),
had little effect on immediately reversing the effects of prior PQQ
deficiency (see Discussion). The mRNA levels for serine palmitoyl
transferase, as well as its functional activity were also decreased
(PQQ2 vs. PQQ+,p ,0.1, Figure 3). The decreases in SPT
mRNA and functional activity paralleled the variable, but
consistent decreases in plasma sphingomyelin in young and adult
rats (cf. Table 2, Table S8, and Figure 1).
Glucose, Insulin, NEFA, and b-BHA
Several experiments were performed in which PQQ was
administered interparentenially, or rats were subjected to the
dietary deprivation protocol. The data in Table 3 indicate for
young Sprague-Dawley rats that fasting glucose and insulin
concentrations were not significantly affected by either change in
dietary status or acute PQQ administration (i.p.). However, PQQ
administration (i.p.) to rats fed PQQ2 diets caused a decrease in
non-esterified free fatty levels (NEFA). Similar results were
obtained using adult Sprague-Dawley rats (Figure 4). Although
plasma glucose levels was slightly higher following oral glucose
tolerance testing in PQQ deprived rats (Figure 4A), the difference
(PQQ2 vs. PQQ+) at each time point was not highly significant.
Clear differences were also not observed in circulating plasma
NEFA before or following oral glucose administration
(Figure 4B). The administration of PQQ (i.p.) also did not alter
significantly basal plasma glucose or insulin levels (Figures 4C
and D).
As an additional validation of these findings, the availability of
the UC Davis type-2 diabetic model rat (UCD-T2DM) [22]
allowed the testing of whether PQQ can influence glucose
tolerance in animals with existing diabetes. The data in
Figure 5 indicate that modest changes in oral glucose tolerance
may occur in response to PQQ administration. The area under
the respective curves was reduced by 7 percent when rats given
saline was compared to rats administered PQQ for 3 days at
4.5 mg/ kg BW (p,0.09). PQQ was also administered to UCD-
T2DM rats, which were then subjected to a 6 h fast. No
differences were observed (PQQ vs. saline) in plasma glucose or
NEFA concentrations over the test period. For example, at 0, 3,
and 6 h, the values for plasma free fatty acids were 0.4360.02,
0.7660.08, and 0.660.06 mg/dL for rats administered saline; in
contrast, to 0.3960.02, 0.6960.07 and 0.5860.06 mg/dL for rats
administered PQQ. With regard to plasma triacylglyceride levels,
values for control rats fell from 310 mg/dL 649 to 236 mg/dL
637 (i.e., D 74 mg triglyceride/dL) over the period of the 6 h fast
following saline administration. In contrast, PQQ administration
resulted in a greater than a 2-fold decrease to 141 mg/dL 628
(p,0.05) or a D169 mg change in triglyceride/dL.
That PQQ administration caused changes in lipid clearance is
also reflected by a significant increase in b-HBA levels in rats fed
the PQQ2 diet, which were reversed upon PQQ repletion
(Figure 6). These data were taken as an additional indirect or
functional measure of decreased b-oxidation potential due to the
reduction in mitochondrial amount.
Energy Expenditure
Data related to the effects of changing PQQ status on RQ,
VO2,V C O 2, and estimated energy expenditure are given in
Figure 1. Effect of PQQ nutritional status on circulating lipid profiles in weanling rats. Values are expressed as nmol fatty acid/g plasma
and are the means 6 SEM (n=5 per group). Panel A indicates changes in neutral lipids. For TAG and DAG, the asterisk indicates p,0.05. Panel B
indicates changes in the major phospholipids; no differences were observed.
doi:10.1371/journal.pone.0021779.g001
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Values are the mean 6 SEM of relative expression values generated from qPCR measurements (n=5 per group). For cardiac tissue, the expressions of
FABP mRNA (**, p,0.001), acylCoA oxidase (*, p,0.01), and a-methyl CoA racemase (*, p,0.04) were statistically decreased in PQQ2 rats vs. PQQ+
fed rats with trends for PPARa (p,0.2) and PMP4 (p,0.1). For liver, only FABP mRNA levels were clearly decreased (*, p,0.01) in rats fed PQQ2 diets
vs. PQQ+ fed rats (see discussion).
doi:10.1371/journal.pone.0021779.g002
Figure 3. Serine palmityl transferase (SPT) mRNA expression in liver and heart and SPT functional activity levels in liver. Values are
the means 6 SEM (n=5 per group). Although variable, rats fed PQQ2 diets tended (p,0.2–0.3) to have lower values for mRNA expression and
activity (see Discussion).
doi:10.1371/journal.pone.0021779.g003
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with respect to treatments, there was a significant difference in
actual energy expenditure, which could be positively correlated
with mitochondrial amount during periods when the rats were
most active (see Discussion).
PQQ and Cardiac Muscle Function and Protection:
Ischemia Reperfusion
Previously it was reported that PQQ is protective when rats
were subjected to 17 or 30 min of left anterior descending
occlusion when reperfused with PQQ (15–20 mg/kg BW) or given
Figure 4. Glucose, NEFA, and insulin in rats following a glucose challenge. (A) Plasma glucose and (B) NEFA in PQQ+ and PQQ2 fasted rats
given 2 g glucose/kg of body weight by oral gavage. Blood was collected at 2, 5, 15, 30, 60 and 90 min intervals. Although glucose clearance
appeared compromised in PQQ2 rats following a glucose challenge, at each of the time points, there was no statististically significant difference
compared to the PQQ+ group. Similarly, there was no difference in NEFA between groups following the glucose challenge, and no differences
between PQQ+ and PQQ2 rats in baseline plasma glucose (C) or insulin (D).
doi:10.1371/journal.pone.0021779.g004
Table 3. Effects of short term PQQ administration (i.p.) on Plasma Glucose, NEFA, and Insulin levels in Young Sprague-Dawley Rats
(4 weeks old) fed PQQ2 or PQQ+ Diets.
1
Dietary
State Diet PQQ Time (Hours) Glucose (mg/dL) NEFA Insulin
Fed PQQ2 0 mg PQQ/kg BW 0 155633 0.8660.07* 103620
Fed PQQ2 3 mg PQQ/kg BW (PQQ2/+)2 1 7 2 616 0.4960.04 100619
Fasted PQQ+ 0 mg PQQ/kg BW 0 153619 0.5360.06 83621
Fasted PQQ+ 3 mg PQQ/kg BW (PQQ2/+)2 1 7 5 615 0.5060.06 107622
1PQQ was administered at 4.5 mg PQQ/kg BW (n=4 per group) followed by assessment of changes in plasma glucose, NEFA, and insulin. An asterisk (*) indicates
p,0.05 relative to the PQQ+ or PQQ2/+ group in the fed or fasted state.
doi:10.1371/journal.pone.0021779.t003
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reperfusion [10,11]. With regard to dietary exposure, the data
suggest that PQQ dietary exposure may be protective. Four out of
17 rats fed the PQQ- diet did not survive the ischemia reperfusion
protocol, whereas all of the PQQ+ fed rats survived (Table 4).
When a preconditioning protocol was introduced prior to
ischemia reperfusion protocol, left ventricular infarct size was
reduced ,30 % in both PQQ- and PQQ+ rats (P,0.005 by 2-way
ANOVA). In addition to defined areas of ischemia, creatine kinase
was increased 4 to 5- fold. Although as indices, the amount of
tissue observed to be ischemic and the creatine kinase increase
were refractory to PQQ exposure, the values for RCR tended to
be higher in response to PQQ exposure (p,0.1). Further,
malondialdehyde levels were lower in non-ischemic areas vs.
ischemic areas (p,0.05), and in non-ischemic areas, PQQ
exposure resulted in a 30-40 % reduction in MDA levels (p,0.05).
Discussion
We have previously reported that liver from rats fed a diet
deficient in PQQ have fewer mitochondria in liver tissue based on
mtDNA measurements [16-21,25]. In this regard, PQQ appears to
be among a growing number of compounds that seem to improve
mitochondriogenesis and/or function in experimental animal
models. As examples, the nutraceutical use of quercetin [26],
resveratrol [27,28], hydroxytyrosol [29], flavanols, such as epica-
techin gallate [30], and combinations of nutrients, such as R-a-
lipoic acid, biotin, acetyl-L-carnitine, and nicotinamide have been
reported to enhance abnormal mitochondriogenesis or improve
mitochondrial function [31]. In addition, such nutritional treat-
ments often influence the mRNA levels of genes involved in lipid
metabolism, including peroxisome proliferator–activated receptor-
a, carnitine palmitoyl transferase-1 and the activities of mitochon-
drial complex I and II [32], although many of the mechanistic
details are lacking. However, a novel feature for PQQ is that the
mitochondrial-related perturbations occur at relatively low levels of
dietary exposure in rodents (,250–300 nmol/1000 kCal or
4.2 MJ) and pharmacologic doses administered in the low mg/kg
body weight range [17,18]. In contrast, many other biofactors are
needed in the sub to high mM ranges when expressed per 1000 kCal
or 4.2 MJ of typical laboratory diet mixtures [32]. For example,
resveratrol canenhancemitochondriogenesis,butinanimal models,
200–500 mg resveratrol/kg diet are usually used for a response
[33]. From a food perspective, this amounts to more than 100 times
that usually found in a typical bottle of red wine [34]. A minimum
0.2–0.3 mg PQQ per kg of diet seems to support normal growth
and development in mice, which is about 1/2 the requirement for
folic acid in mice (e.g., 0.4 to 0.5 mg folic acid/kg of diet) and close
to the concentration of pyrroloquinoline quinone and PQQ-amino
acid derived products found in human milk solids [2].
For the studies described herein, we chose higher concentration
of PQQ than we have previously used (e.g., 2 or 10 mg PQQ/kg
of diet or 4.5 mg PQQ administered i.p./kg body weight) to better
assure optimal tissue saturation. These amounts (excluding PQQ-
amino acid derived adducts, such as imidizolopyrroloquinoline)
are about 10–50 times those found in human diets based on what
food compositional data are currently available [1,2].
The apparent reduction in the amount of liver mitochondria in
groups of mice [18,21] and rats deprived of PQQ (with recovery
upon PQQ repletion) has been a consistent finding [16,19]. A
statistical difference was not observed in adult rat cardiac muscle
(PQQ- vs. PQQ+, Table 1); however, the pattern was similar to
that for liver and supported by previous functional data in vitro
that indicate PQQ exposure protects cardiac mitochondria
[10,11,13]. Given that most animal models of mitochondrial
dysfunction result in elevated TG or perturbations in lipid
metabolism [35], we infer that the reduction in mitochondrial
amount and presumably function in PQQ deprived rats is a
principal underlying cause for the changes observed in plasma
lipids. In addition, the reduction in FABP and CPT mRNA levels
and their respective products are rate-limiting steps in the delivery
of long chain fatty acids to the mitochondria; thus, may be among
additional factors [36]. Although many details regarding mecha-
nisms remain to be resolved, that PQQ exposure activates CREP
phosphorylation and increases in the expression of PGC-1a,
transcriptions factors NRF1 and 2, and TFAM (transcription
factor A, mitochondrial) are all consistent with induction of
mitochondriogenesis and perturbations in circulating lipids
fractions, because of concomitant alterations in b-oxidation [37].
Regarding the modulation of plasma glucose and insulin by
PQQ administration, although the changes were modest, trends in
the data did not exclude the possibility that at higher concentra-
tions PQQ may be effective. Milne et al. [38] have described novel
activators of SIRT1, whose administration to insulin-resistant
animals improves glucose homeostasis. The molecules, various
Figure 5. Oral glucose tolerance in response to a glucose load
in diabetic UCD-T2DM Rats following the administration of
PQQ (i.p.) at 4.5 mg PQQ/Kg BW for 3 days or saline. The area
under the respective curves was reduced by 7 percent when rats given
saline were compared to rats administered PQQ (p,0.09).
doi:10.1371/journal.pone.0021779.g005
Figure 6. b-hydroxybutryic acid levels in rats fed the PQQ2 or
PQQ+ diets. The increase in b -hydroxybutryic acid was reversed upon
PQQ repletion (p,0.05).
doi:10.1371/journal.pone.0021779.g006
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linked to increased mitochondriogenesis and attenuating insulin
resistance in animal models, such as the Zucker fa/fa rats and
genetically obese mice (Lep
ob/ob). The doses of resveratrol or the
analogs ranged from 100–1000 mg per kg body weight, i.e. ,20-
200 the amounts of PQQ that were given intraperitoneally.
Accordingly, higher doses of PQQ might be considered in future
studies. Moreover, we previously identified the insulin receptor
and carbohydrate metabolism as possible targets for PQQ using
Ingenuity pathways analysis software (http://www. ingenuity.
com/index.html [19]). The Ingenuity based analysis indicated that
PQQ repletion of PQQ deprived rats, using a protocol similar to
the one described herein, caused a 2-fold increase in several of the
insulin-induced family of genes (e.g., insulin induced gene 2) and a
2-fold decrease in insulin degrading enzyme.
We also found it of interest that in addition to modest increases
in plasma lysophosphatidylcholine, phosphatidylcholine, and
phosphatidylethanolamine levels upon acute repletion of rats with
PQQ (i.p.) fed the PQQ- diet), there were reductions in plasma
sphingomyelin levels in PQQ-deprived adult and weanling rats.
The changes in plasma phospholipids were assumed related or
linked to cellular membrane changes associated with tissue
remodeling. Although not statistically significant, we focused on
changes in sphingomyelin levels, because of corresponding
decreases in serine palmityl transferase based on measurement of
both functional activity and SPT mRNA levels and previous gene
array analysis [19]. Sphingolipids also facilitate formation of more
mechanically and chemically stable plasma membrane lipid
bilayers [39,40]. Moreover, ceramides and sphingosine (as
sphingosine-1-phosphate), whose formation is dependent on serine
palmitoyl transferase, are also involved in cell signaling, apoptosis,
and cardioprotection [41–43]. Regarding other fatty acid
modifications, there were no consistent changes in the concentra-
tions of PUFAs with chain lengths of .20 carbons nor in the in the
n6/n3 ratio, or concentration of Mead acid (20:39(n-9), (5Z, 8Z,
11Z)-Eicosa-5, 8, 11-trienoic acid) in the major lipid fractions. C20-
C22 PUFAs were examined because they often function in key cell
signaling steps and govern the expression of a wide array of genes,
for example, down-regulation of hepatic lipogenic genes while up-
regulating genes associated with fatty acid oxidation [44–46].
We also examined the expression of five genes selected to
ascertain the extent to which PPAR activation and cellular fatty
acid transport may contribute to the disturbances in lipid
metabolism in PQQ- rats. Liver and cardiac fatty acid-binding
proteins (FABP) are abundant proteins that bind most of the long
chain fatty acids present in the cytosol. Their cytosolic levels
provide an additional control on b-oxidation [47–50]. Liver and
cardiac FABP mRNA levels (FABP-1) were reduced 50% or more
in PQQ- deficient rats. Although changes in FABP mRNA levels
were refractory to PQQ repletion, rat hepatic fatty acid binding
protein is relatively long-lived (,3 days). For example, Bass et al
[50] have reported that following a 48-h fast, total liver FABP
decreases 65% and re-feeding for 24 h does not lead to a
significant recovery of liver FABP.
As markers for potential peroxisomal regulation, acyl-coenzyme
A oxidase 1, PPARa, peroxisomal membrane protein 4, and a-
methyl CoA racemase were examined. It was expected that if
PQQ functions through cAMP-responsive transcription factor
regulated pathways, each of the selected peroxisomal components
would be influenced to some degree in keeping with the changes in
mitochondrial components. Although some of the changes were
not significant, all of the genes used as markers were reduced from
10-45 % in PQQ- rats and most were increased or normalized
upon PQQ repletion. With regard to specific changes, it is
noteworthy that the changes liver PPARa were modest. Likewise
using Hepa1–6 cells in culture, although PQQ exposure causes
activation of the PGC-1a and related genes important to
mitochondrial activation, little effect on PPARa was observed
(Figure S1). As a consequence, we infer that the effects of PQQ
may be more related to stimulation of mitochondrial signaling,
and perhaps FABP expression, than acting as a specific PPAR
agonist.
Importantly, a relationship between the amount of mtDNA/
nuclearDNA in liver and energy expenditure (estimated from
oxygen consumption) was also observed. It has previously been
reported that changes in oxidative capacity as little as 20 percent
can have a direct influence on the sensitivity of cytosolic
respiratory control and has important consequences in the
maintenance of cellular energy balance [51–53]. Our results are
keeping with such observations and help to link PQQ and non-
fasting energy expenditure to the mitochondrial amount. Although
Figure 7. Changes in RQ and energy expenditure (oxygen
consumption) in weaning rats derived from dams fed PQQ2
and PQQ+ diets. No differences in apparent meal frequency or RQ
over the 24-h period of observation. The aggregate energy expenditure
in the fed state (n=10 for each group) was reduced in rats fed PQQ-
diets (p,0.05) compared to PQQ+ rats.
doi:10.1371/journal.pone.0021779.g007
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had lower estimates of VCO2 and VO2. As a final point,
pharmacologic doses of PQQ (,3 mg/kg body weight or greater)
are cardioprotective in models of ischemia reperfusion injury
[10,11,13]. The observation of 30–40 percent mortality in rats
nutritionally deprived of PQQ in response to ischemia adds an
interesting dimension to the cardioprotective effects of PQQ. Tao
et al. [13] have also proposed that such cardioprotection may be
result of increased antioxidant defense as a result of PQQ
exposure. The work summarized herein adds as an additional
consideration, i.e. increased mitochondrial oxidative efficiency in
part related to increased mitochondriogenesis. We interpret the
pattern observed for changes in MDA levels in heart sections as a
reflection of differences in tissue viability. The MDA values were
1.5 to 2.5 fold higher in ischemic sections. For both tissue
conditions (ischemia vs. non-ischemia), relatively lower values for
RCR were accompanied by higher MDA values. Compared to
non-ischemic sections of heart, it is predictable that low values for
the rate of respiratory control and ischemia would lead to
augmentation of lipid peroxidation.
In summary, rats fed a diet deficient in PQQ are metabolically
challenged, due to decreased mitochondria number. In addition
to previously reported perturbed amino acid metabolism, PQQ
deficient rats also have defects in lipid and energy metabolism
and are vulnerable to ischemic insult. Taken together, PQQ is
a novel metabolic modulator involved in many aspects of
mitochondriogenesis, mitochondrial metabolic function as well
as being a cardioprotectant.
Materials and Methods
Reagents, Animal Care, and Nutritional Protocols
Chemicals and reagents used in diets and assays were obtained
from Fisher Chemicals and Sigma–Aldrich and were of the highest
purity available. Amino acids for diet preparations were purchased
from Ajinomoto Co., Inc. Reverse transcription and PCR enzymes
and reagents were obtained from Applied Biosystems or BioRad.
Animal Research Services at the University of California, Davis
(Animal welfare assurance number, A-3433-02) and the VA
Medical Center, UC San Francisco (Animal welfare assurance
number, A-3476-01), approved the animal protocols for the
nutritional studies (protocol 12998, RBR, UCD) and surgery
related to ischemia reperfusion (protocol 03-051-01, JSK, VAMC
UCSF). The American Association for the Accreditation of
Laboratory Animal Care has accredited both facilities. All aspects
of the work were conducted in keeping with established guidelines
(Guide for the Care and Use of Laboratory Animals, NIH Publication
No. 85-23, revised 1996). In addition, the work conducted at UC
Davis (animal husbandry) followed USDA guidelines (Registration
number, 93-R-0433).
Male Sprague-Dawley rats (n=4–10 for given groups) were
obtained commercially (Charles River, Wilmington, MA) and
Figure 8. Relationship between relative mitochondrial amount (liver) and energy expenditure. In panel A the relationship between
mitochondrial amount (mtDNA/nuclearDNA ratio) and energy expenditure in the light fed (squares) and dark fed (circles) for weanling rats fed PQQ-
(open, n=6) or PQQ+ (closed, n=5) diets are shown; R,0.6. Little or no relationship was observed when rats were fasted (e,PQQ-;X, PQQ+). In panel
B, the average energy expenditure in both fed states minus the fasted state are compared. (Light and dark fed states) - (fasted state) are expressed
relative to the mtDNA/nuclearDNA ratio. R was increased to ,0.9. In panel C are data for the relative mitochondrial amount (mtDNA/nuclearDNA
ratio). The average difference mitochondrial amount (,10 %) was not significant for rats that were randomly selected out of a pool of 10 for each
group (see Figure 6). In panel D are values for the fed and fasted states. The average decrease in total energy expenditure (PQQ- vs PQQ+)
approached significance (p,0.1), when values for the fasted state (taken as a rough approximation of basal energy) were subtracted from the values
for the two fed states (light and dark).
doi:10.1371/journal.pone.0021779.g008
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Bedding, (International Absorbents Corp, Bellingham, WA) in a
temperature-controlled facility with a 12-h dark/light cycle and
allowed to consume deionized water and purified amino acid
based diet with or without PQQ ad libitum. Separate experiments
focused on PQQ and indices important to lipid metabolism
assessment and changes in glucose. In some the experiments, the
effects of PQQ administration on glucose regulation were also
examined in rats that were developed as a model of type-2
diabetes, the UCD-T2DM rat [22].
Rats were fed an amino acid based diet devoid in PQQ that
provided all known required nutrients in sufficient quantities to
provide maximal growth. The composition of the basal diet was
identical to that reported by Steinberg et al [17,18] and Stites et al
[21]; the basal PQQ concentration ranged between 5–20 fmol/g
diet. PQQ was added to diets at 0 (PQQ2) or 2 mg/kg
(,6 nmol/g) (PQQ+). Rats were fed diets for at least 4 weeks
prior to selection for given sets of assays (see Figure and Table
legends). For some experiments, a subset of PQQ- rats was
repleted with PQQ (intraperitoneal, i.p., injections of 4.5 mg/kg
PQQ per day (PQQ2/+) for 3 days. Unless indicated in Figure or
Table legends, rats were usually fasted for 4 hrs and anesthetized
by CO2 inhalation prior to blood and tissue collections. Blood was
collected by cardiac puncture into heparinized syringes. Plasma
was separated by centrifugation at 2,000 x g for 15 min at 4uC and
stored at 220uC until analyzed.
PQQ Estimation
PQQ was extracted from tissue and plasma as previously
described [17,18]. A glucose dehydrogenase (GDH)–based assay
system was used for PQQ quantization [21,54]. Recoveries based
on samples (plasma and liver extracts) spiked with PQQ were good
(e.g. .85%).
Plasma Glucose, Insulin, and Free Fatty Acid Levels
To assess oral glucose tolerance, Sprague-Dawley rats were fed
either the PQQ- or PQQ+ diet for 4 (young rats) or 8 weeks (adult
rats). The rats (4/group) were examined in the fed or fasted state
(overnight, 8–10 h). Blood was collected from the tail vein. After a
baseline collection, 2 g glucose/kg of body weight (BW) was given
by oral gavage and blood was collected at 2, 5, 15, 30, 60 and
90 m intervals to assess glucose tolerance. Plasma glucose was
measured using a glucose analyzer (Analox GM7 Microstat,
London, UK). In some experiments, insulin was also measured
using a rat insulin RIA kit (Millipore, St. Charles MO). Non-
esterified fatty acid levels were measured using a NEFA kit (Wako,
Richmond, VA). The assays kits that were used each gave
excellent precision and recovery without the need for extraction.
The short-term effects of PQQ administration on glucose
regulation were examined in both Sprague-Dawley rats and rats
that weredeveloped asa modeloftype-2diabetes,theUCD-T2DM
rat [22]. The model was created by crossing obese Sprague-Dawley
rats with polygenic adult onset obesity and insulin resistance with
Zuckerdiabeticfatty(ZDF)-leanratsthathaveadefectinpancreatic
b-cell function, but normal leptin receptor function. These rats
(n=8pergroup)werefedeitherthePQQ+orPQQ-diet.PQQwas
also administered (i.p.) at 4.5 mg PQQ/kg BW to one-half of the
rats in each group, which was immediately followed by assessment
of glucose tolerance or changes in plasma glucose, triacylglycerides
and fatty acid levels over a 2. Values for plasma glucose were
,350 mg/dL for the UCD-T2DM and ,150 mg/dL for Sprague-
Dawley rats, respectively.
Table 4. Dietary PQQ and Protection from an Ischemia/Reperfusion Injury.
Ischemia Protocol and Experimental Groups
1
Parameter Ischemia/Reperfusion (I/R) Preconditioning plus Ischemia/Reperfusion (P/I/R)
PQQ+ (n=8) PQQ- (n=8){ PQQ+ (n=7) PQQ- (n=9)
Body Weight (g) 37768.7 37069.9 38768.3 38665.6
Heart weight (g) 1.1260.07 1.2060.05 1.1660.07 1.2160.04
LV weight (g) 0.8760.04 0.9060.03 0.8760.04 0.9360.02
Heart/BW (%) 0.3060.01 0.3260.01 0.3060.02 0.3160.01
Mortality (%)
1 0 37.5 (3/8)
1 0 11.1 (1/9)
1
Infarct/LV (%) 24.261.7 23.762.3 16.862.9
2 17.761.8
2
CK Base-line (U/L) 7946167 5376114 4806147 10266355
CK 2 h reperfusion (U/L) 23406258
3 18426280
3 19876360
3 23976400
3
CK (Fold increase) 3.7360.35 4.2360.89 5.1261.0 4.3461.4
RCR-ischemic 2.8560.46 2.5760.47 4.1760.62
4 3.6460.33
4
RCR-non-ischemic 4.9460.28 4.3560.46
4 5.1760.35 4.4360.37
4
MDA-ischemic 508676 359673 Q 375666 344684 Q
MDA-non-ischemic 194619
5 247645 q
5 202643
5 331669 q
5
1Four rats in the PQQ- group died during either I/R or P/I/R protocols compared to none in the PQQ+ group (p,0.1, chi square analysis). In the I/R-PQQ- group, one rat
died of acute pulmonary edema before surgery, one after opening the chest, and one late during reperfusion. The latter heart was salvaged and is included for the
estimates of infarct/LV (left ventricular)%, CK (creatine kinase) levels, RCR (mitochondrial respiratory control ratio) and MDA (malondialdehyde) levels. Two rats in the
PQQ+ group died before suture of LAD and were excluded.
2The P/I/R protocol reduced LV infarct size ,30 percent (I/R vs. P/I/R, P,0.005).
3CK levels were increased ,4-5+ fold following I/R (p,0.01). The increase was refractory to PQQ exposure.
4The RCR in ischemic areas of the LV was improved with preconditioning (p,0.05). In non-ischemic areas of the LV, the RCR tended to be higher in response to PQQ
exposure (p,0.1).
5MDA levels were lower in non-ischemic areas vs. ischemic areas (p,0.05). In non-ischemic ares, PQQ exposure resulted in a 30-40 % reduction in MDA levels (p,0.05).
doi:10.1371/journal.pone.0021779.t004
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A quantitative profile of plasma lipid metabolites was generated
from PQQ- and PQQ+ rats (5/group) (Lipomics Technologies
Inc, now Tethys Bioscience (cf. http://www.lipomics.com/). The
lipids were extracted in the presence of authentic internal
standards by the Folch method (chloroform/methanol (2:1 v/v).
Individual lipid classes were separated by liquid chromatography.
Each lipid class was next transesterified in 1% (v/v) sulfuric acid in
methanol under a nitrogen atmosphere at 100uC for 45 m. The
resulting fatty acid methyl esters were extracted from the mixture
with hexane containing 0.05% butylated hydroxytoluene and
prepared for gas chromatography under nitrogen. Fatty acid
methyl esters were separated and quantified by capillary gas
chromatography (Agilent Technologies model 6890) equipped
with a 30 m DB-88MS capillary column (Agilent Technologies)
and a flame-ionization detector.
In addition, as an indirect marker of b-oxidation, serum b-HBA
levels were measured using a commercial assay kit obtained from
Catachem, Inc. (Bridgeport, CT). The assay is based on the
conversion of D-3-hydroxybutyrate by D-3-hydroxybutyrate
dehydrogenase to acetoacetate as described by Bergmeyer [55].
Metabolic Data and Body Composition
The respiratory quotient (RQ), VO2,V C O 2 and energy
expenditure (EE) for individual rats were measured using PQQ-
and PQQ+ rats (n=8 per group). Metabolic monitoring was carried
out with energy expenditure analysis system (AccuScan Instruments,
Columbus, Ohio, United States) located in the UC Davis
Department of Nutrition animal facility. The system consists of an
O2 analyzer, CO2 analyzer, and PhysioScan analyzer that can
monitor vertical and horizontal movement via light beam interrup-
tion. A flow controller/channelyzer allows for flow rate adjustments
and sequential channeling of airflow from a reference line and the
four animal chambers through the CO2 and O2 analyzers. The flow
rate for these experiments was 0.5 l/m. The dimensions of the
plexiglas chambers are 29 cm (L) X 19 cm (H) X 13 cm (W).
The Integra ME software includes O2 and CO2 analyzer
calibration, data collection, and analysis programs. Reported and
calculated values include O2 consumption, CO2 production, RQ,
heat production (energy expenditure), total ambulatory move-
ment, and total rest time. Animals were acclimated to the
chambers for 4–6 h prior to a 24-h data collection period. Each
animal received its assigned diet and water while in the chamber.
Measurements were made over a 36 hrs in both the fed/dark, fed/
light, and fasted/dark states (,12 hr ea).
Body fat mass and lean mass were determined following whole
body fat extraction as described by Bell et al [56].
Mitochondrial DNA, mRNA Expression and qRT-PCR, and
Serine Palmitoyl Transferase Activity
The relative amounts of liver mitochondria in rats were
determined using quantitative real time PCR (qRT-PCR) methods
as previously described [16,19–21]. The primers for the targeted
genes are given in Table 5. The nuclear cystic fibrosis (CF) gene
and mitochondrial nicotinamide adenine dinucleotide dehydroge-
nase-5 (ND-5) gene were used to assess the relative mitochondrial
copy number to nuclear copy number [16,57].
PCR was performed using an ABI 7900HT real time
thermocycler (Perkin Elmer) coupled with SYBR Green technol-
ogy (Applied Biosystems) and the following cycling parameters:
stage 1, 50uC for 2 m; stage 2, 95uC for 10 m; stage 3, 40 cycles
for 95uC for 15 s; 60uC for 1 m; and stage 4, 95uC for 15 s. The
linearity of the dissociation curve was analyzed using the ABI
7900HT software. Each sample was analyzed in duplicate. The
mean cycle time of the linear part of the curve was designated Ct.
Relative mitochondrial copy number to nuclear copy number was
assessed by a comparative Ct method (DCt mitochondria/nuclear
= Ct mitochondriaCt 2 Ct nuclearCt) to assess for the fold-change
for mtDNA/nuclear DNA from PQQ2, PQQ+, PQQ2/+ and
PQQ+/2 rats.
For qRT- PCR assays, RNA was extracted with Trizol
(Invitrogen) and cDNAs were generated from 1 mg total RNA
(Reverse Transcription Kit, Applied Biosystems, Foster City, CA)
following the manufacturer’s instructions. When needed, gene
specific primers were selected (Table 5) using Primer ExpressH
Software (Applied Biosystems).
Serine palmitoyl transferase (palmitoyl-CoA:L-serine C-palmi-
toyl transferase (decar-boxylating), EC 2.3.1.50) was measured
based on the incorporation of
3H-serine into the chloroform-
soluble product 3-ketosphinganine in microsomal subfractions as
described by Williams et al [58].
Ischemia Reperfusion and Infarct Size
The effects of PQQ on cardiac function were tested using an
ischemia reperfusion model [10,11]. Rats were anesthetized using
pentobarbital (50 mg/kg body weight) by intraperitoneal injection.
A tracheotomy was then performed and ventilation was main-
tained using a Harvard Rodent Respirator (Model 683, Harvard
Apparatus, Holliston, Mass) as described previously [10,11]. The
level of consciousness of each animal was monitored by lack of
Table 5. PCR Primers.
Gene Forward Reverse
Cystic Fibrosis gene, Nuclear (CF) AAACTCAGGATAGCTGTCCGTTTAG GCCAAATGATAGCATGGAACTCT
NAD dehydrogenase-5 (ND-5) GGATGATGATATGGCCTTGCA CGACTCGGTTGTAGAGGATTGC
Liver Fatty Acid Binding Protein (FABP1) TGTAGCCCATACTGGCCTCAA TTCAGGTTTTCCAGCATTCATG
PPAR a TGGAGTCCACGCATGTGAAG CGCCAGCTTTAGCCGAATAG
Peroxisomal membrane protein 4 (Pmp4) CAGCTAAGGATTCCAGATGCTCTT AGGCCCAGAGAGGGTTGAA
Acyl CoA oxidase (Acox1) TGCTGGCATCGAAGAATGTC AATCCCACTGCTGTGAGAATAGC
Carnitine Palmityl Transferase (CPT) TGGGAGCGACTCTTCAATACTTC TTGATATGTTGGATGGTGTCTGTCT
Methyl CoA racemase GACCCCAGTGCTGACTCTTGA TGAAGGAGCCCCGTTCTCT
Serine palmityl transferase (SPT) AATGCGCTCGCTTCTGTTG GCCAGAGAGCCGCTGATG
Actin GGCGCTTTTGACTCAGGATT GGGATGTTTGCTCCAACCAA
doi:10.1371/journal.pone.0021779.t005
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artery snare occluder was placed around the proximal left anterior
descending (LAD) coronary artery through a midline sternotomy.
Rats then underwent 30 m of LAD coronary artery occlusion and
120 m of reflow. For ischemic preconditioning studies, rats
underwent 20 minutes of equilibration followed by 3 minutes of
LAD coronary occlusion. This was followed by 7 minutes of
reflow. Hearts were then subjected to 30 minutes of LAD coronary
artery occlusion and 120 minutes of reperfusion.
Infarct size was measured as described previously. After 120 m
of reperfusion, the LAD was re-occluded, and phthalocyanine dye
(Engelhard Corp, Louisville, KY) was injected into the LV cavity,
allowing normally perfused myocardium to stain blue. The heart
was then excised, rinsed of excess dye, and sliced transversely from
apex to base into 2-mm-thick sections. The sections were
incubated in triphenyltetrazolium chloride (TTC, Sigma) as
described above. Infarcted myocardium fails to stain with TTC.
The tissue sections were then fixed in a10% formalin solution
(Sigma/Aldrich) and weighed. Color digital images of both sides of
each transverse slice were obtained using a video camera (DC 300
F, Leica Microsystems, Wetzlar, Germany) connected to a
microscope (Stereo Zoom 6 Photo, Leica). The regions showing
blue-stained (non-ischemic), red-stained (ischemic but non-infarct-
ed), and unstained (infarcted) tissue were sectioned. Each colored
area was outlined and measured using NIH Image 1.59 software
(National Institutes of Health, Bethesda, MD) in a blinded fashion.
On each side, the fraction of the LV area representing infarct-
related tissue (average of 2 images) was multiplied by the weight of
that section to determine the absolute weight of infarct-related
tissue. The infarct size for each heart was expressed as:
Percentage Infarct size/LV mass = Infarct weight in each slice/Total LV
weight X ,100%
Risk area/LV mass (%) = Total weight of non-blue stained section/
Total LV weight.
Infarct size was then calculated as a percentage of risk area, i.e.
infarct weight in each slice/Risk area weight of each slice. For
these estimates and for malondialdehyde determinations (see
below), rats were euthanized by removal of the heart under
anesthesia at the conclusion of the experiment.
Statistical Analysis
Data were analyzed using one-way analysis of variance and with
a Bonferroni correction or by t-test analysis. Data are presented as
the mean +/2 the standard error (SEM).
Supporting Information
Figure S1 Effect of PQQ on PPARa activation. Mouse
Hepa 1–6 cells were examined to assess whether PPARa expression
was responsive to the addition of PQQ. The cells were plated in 12-
well plates and transfected with mouse PPARa and pSV-b-
galactosidase expression vectors and PPARa luciferase reporter
vector (Promega Corp., Madison, WI). The pSV-b-galactosidase
vector was used to monitor transfection efficiency (Promega Corp.,
Madison, WI). Luciferase activities were measured using the Dual
Luciferase Reporter assay system kit (Promega). Homogenates from
cells were prepared with 500 mL of PLB (passive lysis buffer,
Promega Corp.). Cells were lysed in agitation for 15 min. 20 mLo f
homogenate was used for measurement. After 16 h, cells were
incubated with PQQ or 10 mM WY-14643 (a known PPAR-a
agonist) for 24 h. Cell lysates were extracted and analyzed for
PPAR-a activation, as detected by luciferase activity, and
normalized for transactivation efficiency by b-galactosidase activity.
The data represent the mean 6 SD for 6 independent
determinations and represents transactivation relative to the control
condition(setat 100%).Means with asterisksdifferfrom thecontrol,
as analyzed by one-way ANOVA (**, p,0.01).
(TIFF)
Table S1 The values for individual fatty acids as
components of major classes of plasma neutral and
phospholipids given in Tables S1–S8. The data are for adult
rats fed PQQ- or PQQ+ diets (n= 4 to 5 per group) plus 3
additional rats fed the PQQ- diet and repleted with PQQ at
4.5 mg/kg BW (PPQ2/+) for 3 days prior to assays. To assess
trends in the data, t-tests (two-tailed) were carried out.
(DOC)
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